The document summarizes CMC (chemistry, manufacturing and controls) regulatory affairs for pharmaceutical products. It discusses the CMC section of regulatory filings which contains information on drug substance and product characteristics, manufacturing and quality. It describes the chemistry, manufacturing process, specifications and controls for ensuring consistent quality batches. It also covers CMC regulatory compliance after approval and post-approval regulatory requirements to ensure continued safety and effectiveness. The goal of CMC regulatory affairs is to provide the necessary CMC information and strategy to obtain and maintain regulatory approvals.
CMC, post approval regulatory affairs, etcJayeshRajput7
this document covers points such as CMC, post approval regulatory affairs, regulation for combination products, and medical devices, common technical document (CTD) and electronic common technical document (eCTD) format, industry and FDA liasion, ICH guidelines of ICH Q,S,E,M, regulatory requirements of EU, MHRA, TGA and ROW countries.
Investigational medical product dossierSachinFartade
Investigational medical product dossier is document made to apply for clinical trial application in European Union. European Medical Agency is regulatory body for drug approval in European Union.
CMC, post approval regulatory affairs, etcJayeshRajput7
this document covers points such as CMC, post approval regulatory affairs, regulation for combination products, and medical devices, common technical document (CTD) and electronic common technical document (eCTD) format, industry and FDA liasion, ICH guidelines of ICH Q,S,E,M, regulatory requirements of EU, MHRA, TGA and ROW countries.
Investigational medical product dossierSachinFartade
Investigational medical product dossier is document made to apply for clinical trial application in European Union. European Medical Agency is regulatory body for drug approval in European Union.
regulations for combination products .KeerthanaN20
Combination product includes:
(1) A product comprised of two or more regulated components, i.e., drug/device, biologic/device, drug/biologic, or drug/device/biologic, that are physically, chemically, or otherwise combined or mixed and produced as a single entity;
(2) Two or more separate products packaged together in a single package or as a unit .
(3) A drug, device, or biological product packaged separately that according to its investigational plan or proposed labeling is intended for use only with an approved individually specified drug, device, or biological product where both are required to achieve the intended use, indication, or effect and where upon approval of the proposed product the labeling of the approved product would need to be changed, e.g., to reflect a change in intended use, dosage form, strength, route of administration, or significant change in dose;
stability The ability of a pharmaceutical product to retain its chemical, physical, microbiological and biopharmaceutical properties within specified limits throughout its shelf-life.Why is stability of a drug important?
Drug stability affects the safety and efficacy of the drug product; degradation impurities may cause a loss of efficacy and generate possible adverse effects. Therefore, achieving the chemical and physical stability of drugs is essential to ensure their quality and safety.Common factors that affect this stability include temperature, light, pH, oxidation and enzymatic degradation. Special considerations are also required when dealing with chiral molecules, deuterated internal standards and large biomolecules.
This presentation consist a consolidated list all Regulatory Guidelines for Cleaning Validation. Hyperlink of the applicable guidelines are also given in the presentation.
What Is An Assistant Drug Controller (Adc) Noc In India And Why Is It Importa...PranshuCorpseed
The pharmaceutical industry plays a pivotal role in public health by manufacturing and distributing drugs and medical products. To ensure the safety, quality, and efficacy of pharmaceuticals, governments around the world have established stringent regulatory frameworks. In India, the Assistant Drug Controller (ADC) assumes a crucial role in this regulatory process. This article delves into the significance of an Assistant Drug Controller (ADC) No Objection Certificate (NOC) in India and its pivotal role in the pharmaceutical sector.
DERIVATION OF MODIFIED BERNOULLI EQUATION WITH VISCOUS EFFECTS AND TERMINAL V...Wasswaderrick3
In this book, we use conservation of energy techniques on a fluid element to derive the Modified Bernoulli equation of flow with viscous or friction effects. We derive the general equation of flow/ velocity and then from this we derive the Pouiselle flow equation, the transition flow equation and the turbulent flow equation. In the situations where there are no viscous effects , the equation reduces to the Bernoulli equation. From experimental results, we are able to include other terms in the Bernoulli equation. We also look at cases where pressure gradients exist. We use the Modified Bernoulli equation to derive equations of flow rate for pipes of different cross sectional areas connected together. We also extend our techniques of energy conservation to a sphere falling in a viscous medium under the effect of gravity. We demonstrate Stokes equation of terminal velocity and turbulent flow equation. We look at a way of calculating the time taken for a body to fall in a viscous medium. We also look at the general equation of terminal velocity.
Nutraceutical market, scope and growth: Herbal drug technologyLokesh Patil
As consumer awareness of health and wellness rises, the nutraceutical market—which includes goods like functional meals, drinks, and dietary supplements that provide health advantages beyond basic nutrition—is growing significantly. As healthcare expenses rise, the population ages, and people want natural and preventative health solutions more and more, this industry is increasing quickly. Further driving market expansion are product formulation innovations and the use of cutting-edge technology for customized nutrition. With its worldwide reach, the nutraceutical industry is expected to keep growing and provide significant chances for research and investment in a number of categories, including vitamins, minerals, probiotics, and herbal supplements.
The ability to recreate computational results with minimal effort and actionable metrics provides a solid foundation for scientific research and software development. When people can replicate an analysis at the touch of a button using open-source software, open data, and methods to assess and compare proposals, it significantly eases verification of results, engagement with a diverse range of contributors, and progress. However, we have yet to fully achieve this; there are still many sociotechnical frictions.
Inspired by David Donoho's vision, this talk aims to revisit the three crucial pillars of frictionless reproducibility (data sharing, code sharing, and competitive challenges) with the perspective of deep software variability.
Our observation is that multiple layers — hardware, operating systems, third-party libraries, software versions, input data, compile-time options, and parameters — are subject to variability that exacerbates frictions but is also essential for achieving robust, generalizable results and fostering innovation. I will first review the literature, providing evidence of how the complex variability interactions across these layers affect qualitative and quantitative software properties, thereby complicating the reproduction and replication of scientific studies in various fields.
I will then present some software engineering and AI techniques that can support the strategic exploration of variability spaces. These include the use of abstractions and models (e.g., feature models), sampling strategies (e.g., uniform, random), cost-effective measurements (e.g., incremental build of software configurations), and dimensionality reduction methods (e.g., transfer learning, feature selection, software debloating).
I will finally argue that deep variability is both the problem and solution of frictionless reproducibility, calling the software science community to develop new methods and tools to manage variability and foster reproducibility in software systems.
Exposé invité Journées Nationales du GDR GPL 2024
Seminar of U.V. Spectroscopy by SAMIR PANDASAMIR PANDA
Spectroscopy is a branch of science dealing the study of interaction of electromagnetic radiation with matter.
Ultraviolet-visible spectroscopy refers to absorption spectroscopy or reflect spectroscopy in the UV-VIS spectral region.
Ultraviolet-visible spectroscopy is an analytical method that can measure the amount of light received by the analyte.
Toxic effects of heavy metals : Lead and Arsenicsanjana502982
Heavy metals are naturally occuring metallic chemical elements that have relatively high density, and are toxic at even low concentrations. All toxic metals are termed as heavy metals irrespective of their atomic mass and density, eg. arsenic, lead, mercury, cadmium, thallium, chromium, etc.
Observation of Io’s Resurfacing via Plume Deposition Using Ground-based Adapt...Sérgio Sacani
Since volcanic activity was first discovered on Io from Voyager images in 1979, changes
on Io’s surface have been monitored from both spacecraft and ground-based telescopes.
Here, we present the highest spatial resolution images of Io ever obtained from a groundbased telescope. These images, acquired by the SHARK-VIS instrument on the Large
Binocular Telescope, show evidence of a major resurfacing event on Io’s trailing hemisphere. When compared to the most recent spacecraft images, the SHARK-VIS images
show that a plume deposit from a powerful eruption at Pillan Patera has covered part
of the long-lived Pele plume deposit. Although this type of resurfacing event may be common on Io, few have been detected due to the rarity of spacecraft visits and the previously low spatial resolution available from Earth-based telescopes. The SHARK-VIS instrument ushers in a new era of high resolution imaging of Io’s surface using adaptive
optics at visible wavelengths.
THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.Sérgio Sacani
The return of a sample of near-surface atmosphere from Mars would facilitate answers to several first-order science questions surrounding the formation and evolution of the planet. One of the important aspects of terrestrial planet formation in general is the role that primary atmospheres played in influencing the chemistry and structure of the planets and their antecedents. Studies of the martian atmosphere can be used to investigate the role of a primary atmosphere in its history. Atmosphere samples would also inform our understanding of the near-surface chemistry of the planet, and ultimately the prospects for life. High-precision isotopic analyses of constituent gases are needed to address these questions, requiring that the analyses are made on returned samples rather than in situ.
This presentation explores a brief idea about the structural and functional attributes of nucleotides, the structure and function of genetic materials along with the impact of UV rays and pH upon them.
3. Introduction:-
The chemistry, manufacturing, and controls (CMC) section of a regulatory filing
investigational new drug (IND), IND amendments, IND annual reports, new drug
application (NDA) or biologics license application (BLA), postapproval CMC
supplements, NDA annual reports] contains detailed information pertaining to
the characteristics, manufacturing, and quality aspects of the drug substance
and drug product.
Under the International Conference on Harmonization (ICH) common technical
document (CTD) format, the CMC section is referred to as the quality section
and the structure is outlined in the ICH CTD guidance.
4. What is CMC regulations affairs ?
Pharmaceutical companies are legally required to obtain and maintain
regulatory approvals.
Regulatory Affairs is a discipline and strategic function within the overall
organizational structure of a pharmaceutical company that directly interacts with
government regulatory agencies concerning regulatory approvals.
The Food and Drug Administration (FDA), European Medicines Agency (EMA),
Japanese Pharmaceuticals and Medical Devices Agency (PMDA), for example,
are government regulatory agencies typically involved in the approval process.
5. Chemistry, Manufacturing, and Controls (CMC ) Regulatory Affairs (RA) is a
specific area within RA that has the ultimate responsibility for providing CMC
regulatory leadership and strategy required to achieve regulatory approvals.
As a strategic function, CMC RA collaborates closely with multiple scientific,
technical, quality, and commercial areas within a company or with external
contract manufacturing organizations (CMOs). “To help companies effectively
and efficiently achieve regulatory approvals,”
6. Pharmaceutical Quality :-
The consistency of their quality will be assured from batch to batch. The contents of
these quality sections will evolve with time and experience in both quantity and detail of
information. The quality section of a marketing application (CTD/NDA) describes the
CMC processes for commercial product, and therefore these sections of a marketing
application are very detailed.
However, for an IND application, while the same basic information is required, it may
be supplied in much less detail because of the preliminary stage of development. The
CMC information filed in an IND or NDA/CTD is reviewed by the agency to ensure that
the drug substance and drug product meet the “quality standards” and do not pose any
significant safety risk or compromise efficacy during the intended use in the targeted
patient population.
7. Chemistry :-
Nomenclature :-
All appropriate names or designations for the drug substance
should be provided along with any codes, abbreviations, or nicknames used in the
application to identify the drug substance.
1-Chemical Name .
2-IUPAC Name .
3-International Nonproprietary Names [INNs] .
8. Structure :-
This first section contains only summary information relating to
structure and other characteristics. More detailed information concerning proof
of structure is to be provided in the characterization section. Information that is
expected to be provided here includes
1. One or more drawings to show the overall chemical structure of the drug
substance, including stereochemistry,
2. Molecular formula, and
3. Molecular weight.
For a naturally derived protein drug substance, the information should include
1. The number of amino acid residues,
2. The amino acid sequence indicating glycosylation sites or any other posttranslational
modifications, and
3. A general description of the molecule (e.g., shape, disulfide bonds, subunit
composition)
9. General properties:-
A list of the general physicochemical properties of the drug
substance should be provided. Relevant properties are those physical, chemical,
biological, and microbiological attributes relating to the identity, strength, quality,
purity, and/or potency of the drug substance and, as appropriate, drug product. The
information should include, as appropriate, the following:
1. A general description of the drug substance (e.g., appearance, color,
physical state)
2. Melting or boiling points
3. Optical rotation
4. Solubility profile (aqueous and nonaqueous, as applicable)
5. Solution pH
6. Partition coefficients
7. Dissociation constants
8. Identification of the physical form
9. Biological activities
10. Manufacturng :-
Manufacturer detail. The name, address, and manufacturing responsibility should be provided
for each firm (including contract manufacturers and testing laboratories) and each site (i.e.,
facility) that will be involved in the manufacturing or testing of the drug substance.
Method of manufacture. This section should include a schematic flow diagram that gives the
steps of the manufacturing process and shows where each material enters the process. The
entire manufacturing process from the starting materials to the final drug substance released for
testing should be depicted. This schematic flow diagram should be accompanied by a narrative
description of the manufacturing process that represents the sequence of manufacturing steps
undertaken and should include the scale of production. The narrative provided should include
more details than that provided in the flow diagram. The description should identify all process
controls along with any associated numeric ranges, limits, or acceptance criteria.
11. Controls :-
Control of Drug Substance .
The proposed specifications for the drug substance used to produce the drug product should be
provided. A specification is defined as a list of tests, references to analytical procedures, and
appropriate acceptance criteria, which are numerical limits, ranges, or other criteria for the tests
described.
Guidance on setting specifications is outlined in guidance ICH Q6A; for biotechnology products,
the guidance is outlined in ICH Q6B. The specification establishes criteria to which each batch
of drug substance should conform to be considered acceptable for its intended use.
Conformation to specification means that the drug substance, when tested according to the
listed analytical procedures, will meet the listed acceptance criteria. The specification sheet
should list all tests to which each batch of a drug substance will conform and the associated
acceptance criteria and should also include a reference to the analytical procedures that will be
used to perform each test.
12. Batch analysis, which is a collation of analytical data for all the tests included in the
specifications, should be provided for all drug substance batches used for :-
(i) Nonclinical studies .
(ii) Drug product clinical efficacy and safety,bioavailability, and bioequivalence .
(iii) Primary stability studies.
The information submitted on each of the batches should include a description of the batch. The
description should include the following :-
1. Batch identity (i.e., batch number) and size
2. Date of manufacture
3. Site of manufacture
4. Manufacturing process, where applicable
5. Use of batch (e.g., clinical, stability)
13. CMC REGULATORY COMPLIANCE :-
After review and approval/acceptance of the CMC information by the agency,the CMC
processes and procedures described in the IND/CTD/NDA become a binding commitment.
Thus, all future batches of that particular drug substance and drug product will be manufactured
by the processes and procedures described in the regulatory filing(s) so that they meet the
quality criteria described in the application.
Continuing to maintain this commitment is referred to as CMC Regulatory Compliance.
14. Post approval regulatory affairs :-
The FDA may require a post-approval study at the time of approval of a Premarket Approval
(PMA) , Humanitarian Device Exemption (HDE) , or product development protocol (PDP)
application to help assure continued safety and effectiveness (or continued probable benefit ,i
the case of an HDE) of the approved drug product of medical device .
A sponsor’s failure to comply with any post-approval requirement may be grouns for
withdrawing approval i.e. whether the post approval study will be terminated or revised/replaced
.
15.
16.
17. Conclusion :-
CMC Information for the drug substance and drug product of an investigationaland commercial
drug is provided in the quality module of a dossier submitted in CTD format. It is inevitable that
the information will continue to change because of various improvements and necessities
throughout development and postapproval.
It is the sponsor’s responsibility to perform adequate assessment of the changes to
demonstrate that the changes have adverse affect on the identity,strength, quality, purity, or
potency of the drug as they may relate to the safety or effectiveness of the drug.
Communicating the changes and the change assessments to the FDA by appropriate regulatory
process is critical for maintaining CMC regulatory conformance and complying with the Food,
Drug, and Cosmetic Act.